Blueshift Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Blueshift Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,155	Closed	-$303K	–	500
2023 Q1	$303K	Buy	+8,155	New	+$367K	0.13%	218
2022 Q4	–	Sell	-3,718	Closed	-$260K	–	705
2022 Q3	$260K	Buy	+3,718	New	+$275K	0.06%	442
2021 Q1	–	Sell	-1,745	Closed	-$383K	–	1130
2020 Q4	$383K	Buy	+1,745	New	+$377K	0.05%	467

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Blueshift Asset Management's MRTX Position: Q2 2023 in Review

Blueshift Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 8,155 shares — an estimated $303K sold.

Blueshift Asset Management first reported a position in MRTX in Q4 2020 and held it in 3 quarters. The position peaked at $383K in Q4 2020. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

Blueshift Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Blueshift Asset Management sold 8,155 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $303K.
Blueshift Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
Blueshift Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $383K in Q4 2020.
207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Blueshift Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.